Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark; Pharmaceutical R&D, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Pharmaceutical Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
J Pharm Sci. 2024 Oct;113(10):3054-3064. doi: 10.1016/j.xphs.2024.07.017. Epub 2024 Jul 25.
Enabling drug formulations are often required to ensure sufficient absorption after oral administration of poorly soluble drugs. While these formulations typically increase the apparent solubility of the drug, it is widely acknowledged that only molecularly dissolved, i.e., free fraction of the drug, is prone for direct absorption, while colloid-associated drug does not permeate to the same extent. In the present study, we aimed at comparing the effect of molecularly and apparently (i.e., the sum of molecularly and colloid-associated drug) dissolved drug concentrations on the oral absorption of a poorly water-soluble drug compound, Alectinib. Mixtures of Alectinib and respectively 50 %, 25 %, 12.5 %, and 3 % sodium lauryl sulfate (SLS) relative to the dose were prepared and small-scale dissolution tests were performed under simulated fed and fasted state conditions. Both the molecularly and apparently dissolved drug concentrations were assessed in parallel using microdialysis and centrifugation/filtration sampling, respectively. The data served as the basis for an in vitro-in vivo correlation (IVIVC) and as input for a GastroPlus physiologically-based biopharmaceutics model (PBBM). It was shown that with increasing the content of SLS the apparently dissolved drug in FeSSIF and FaSSIF increased to a linear extent and thus, the predicted in vivo performance of the 50 % SLS formulation, based on apparently dissolved drug, would outperform all other formulations. Against common expectation, however, the free (molecularly dissolved) drug concentrations were found to vary with SLS concentrations as well, yet to a minor extent. A systematic comparison of solubilized and free drug dissolution patterns at different SLS contents of the formulations and prandial states allowed for interesting insights into the complex dissolution-/supersaturation-, micellization-, and precipitation-behavior of the formulations. When comparing the in vitro datasets with human pharmacokinetic data from a bioequivalence study, it was shown that the use of molecularly dissolved drug resulted in an improved IVIVC. By incorporating the in vitro dissolution datasets into the GastroPlus PBBM, the apparently dissolved drug concentrations resulted in both, a remarkable overprediction of plasma concentrations as well as a misprediction of the influence of SLS on systemic exposure. In contrast, by using the molecularly dissolved drug (i.e., free fraction) as the model input, the predicted plasma concentration-time profiles were in excellent agreement with observed data for all formulations under both fed and fasted conditions. By combining an advanced in vitro assessment with PBBM, the present study confirmed that only the molecularly dissolved drug, and not the colloid-associated drug, is available for direct absorption.
为确保口服后吸收较差的药物的充分吸收,通常需要使用药物制剂。虽然这些制剂通常会提高药物的表观溶解度,但人们普遍认为,只有分子溶解的药物(即游离药物部分)才易于直接吸收,而胶体结合的药物则不易吸收。在本研究中,我们旨在比较分子溶解和表观溶解(即分子溶解和胶体结合药物的总和)的药物浓度对一种水溶性差的药物化合物阿来替尼的口服吸收的影响。阿来替尼与 50%、25%、12.5%和 3%十二烷基硫酸钠(SLS)的混合物分别进行了制备,并在模拟进食和禁食条件下进行了小尺度溶解试验。分别使用微透析和离心/过滤采样平行评估了分子溶解和表观溶解的药物浓度。这些数据为体外-体内相关性(IVIVC)提供了基础,并为 GastroPlus 基于生理学的生物药剂学模型(PBBM)提供了输入。结果表明,随着 SLS 含量的增加,在 FeSSIF 和 FaSSIF 中表观溶解的药物呈线性增加,因此,基于表观溶解的药物,50% SLS 制剂的预测体内性能将优于所有其他制剂。然而,与普遍预期相反,发现游离(分子溶解)药物浓度也随 SLS 浓度而变化,但变化较小。在不同 SLS 含量的制剂和进食状态下,对溶解/过饱和、胶束化和沉淀行为进行系统比较,使我们对制剂的复杂溶解/超饱和、胶束化和沉淀行为有了有趣的了解。当将体外数据集与生物等效性研究中的人体药代动力学数据进行比较时,结果表明,使用分子溶解的药物可提高 IVIVC。通过将体外溶解数据集纳入 GastroPlus PBBM,表观溶解的药物浓度不仅导致对血浆浓度的显著高估,还导致对 SLS 对全身暴露影响的错误预测。相比之下,通过使用分子溶解的药物(即游离部分)作为模型输入,对于所有制剂,在进食和禁食条件下,预测的血浆浓度-时间曲线与观察数据非常吻合。通过将先进的体外评估与 PBBM 相结合,本研究证实,只有分子溶解的药物,而不是胶体结合的药物,可直接吸收。